PurposeThis study aims to assess adherence to luteinising hormone-releasing hormone (LHRH) agonist treatment for prostate cancer (PC) in England, considering formulation-related differences, their imp
1Smear positive and/or culture positive for MTBC. 2Chest x-ray and clinical work-up were not performed for the majority of inmates screened in exit screening; thus there were no clinical diagnoses; as
